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ABSTRACT: The self-assembly of amyloid peptides (Aβ), in particular
Aβ1−42, into oligomers and fibrils is one of the main pathological events
related to Alzheimer’s disease. Recent studies have demonstrated the
ability of carbon monoxide-releasing molecules (CORMs) to protect
neurons and astrocytes from Aβ1−42 toxicity. In fact, CORMs are able to
carry and release controlled levels of CO and are known to exert a wide
range of anti-inflammatory and anti-apoptotic activities at physiologically
relevant concentrations. In order to investigate the direct effects of
CORMs on Aβ1−42, we studied the reactivity of CORM-2 and CORM-3
with Aβ1−42 in vitro and the potential inhibition of its aggregation by mass
spectrometry (MS), as well as fluorescence and circular dichroism
spectroscopies. The application of an electrospray ionization-MS (ESI-
MS) method allowed the detection of stable Aβ1−42/CORMs adducts,
involving the addition of the Ru(CO)2 portion of CORMs at histidine
residues on the Aβ1−42 skeleton. Moreover, CORMs showed anti-aggregating properties through formation of stable adducts
with Aβ1−42 as demonstrated by a thioflavin T fluorescence assay and MS analysis. As further proof, comparison of the CD
spectra of Aβ1−42 recorded in the absence and in the presence of CORM-3 at a 1:1 molar ratio showed the ability of CORM-3
to stabilize the peptide in its soluble, unordered conformation, thereby preventing its misfolding and aggregation. This multi-
methodological investigation revealed novel interactions between Aβ1−42 and CORMs, contributing new insights into the
proposed neuroprotective mechanisms mediated by CORMs and disclosing a new strategy to divert amyloid aggregation and
toxicity.
1. INTRODUCTION
The aggregated forms of amyloid beta peptide (Aβ) have a
significant correlation with a growing number of diseases,
including but not limited to neurodegeneration.1 Indeed, the
assembly of misfolded amyloid peptides into cytotoxic
oligomeric and β-sheet-rich fibrillar aggregates2 is one of the
major pathological events that occur in the progression of
Alzheimer’s disease (AD).3,4 The synaptotoxicity of Aβ
oligomers,5−8 along with their neurotoxicity and pro-
inflammatory effects of Aβ fibrils9 make targeting Aβ assembly
an interesting therapeutic approach to treat AD.10 The effects
of Aβs are not restricted to neurons as increasing evidence
indicates a modulation of glia physiology.11−13 It has been
reported that deposition of Aβs leads to an impairment of
astrocytic function14 and that astrocytes may undergo atrophy
and degeneration at the early stages of disease progression in
animal models of AD as a result of Aβ exposure.15,16 Because
of their fundamental role in ionic homoeostasis and cell
regeneration, astrocyte dysfunction contributes to brain aging
and neurodegeneration. Recently, the use of endogenous
molecules to protect neurons from Aβ1−42 toxicity by
modulation of neuronal or glia processes has been explored.
Carbon monoxide (CO) is a well-established gaseous toxic
molecule.17 Exposure to elevated levels of environmental CO is
suggested to promote cognitive decline.18 However, recently,
CO has received growing attention due to its ability to
modulate an array of cell signaling cascades pertinent to
neurodegeneration.19−23 These studies have used a wide array
of reagents to investigate the role for CO: (1) heme oxygenase-
1 induction; (2) CO releasing molecules (CORMs); or (3)
exposure to CO gas, highlighting a distinct role for both
endogenous and exogenous CO. These studies have
demonstrated the ability of CORMs to protect both neurons
and astrocytes from Aβ1−42 toxicity in vitro
22,23 and have
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highlighted distinct cellular pathways involved in the
cytoprotective effects of CORMs. For example, exposure of
astrocytes to CO has been reported to result in a reduction of
Aβ1−42 toxicity via inhibition of NADPH oxidase-derived
reactive oxygen species (ROS) production. In contrast,
neuronal protection was facilitated by CO suppression of
AMP-activated kinase mediated by Aβ1−42.
24 Based on these
studies and other reports,25,26 the opportunity of preventing
amyloid-induced cellular degeneration through the use of CO
donors or heme oxygenase-1 (HO-1) induction22,23 deserves
further investigation.27 In this context, the present work also
aimed at assessing additional mechanisms responsible for the
reported CORM-mediated reduction of amyloid toxicity in
living cells.22,23 The use of CORMs such as CORM-2 and
CORM-3 (Figure 1) precisely suits this purpose. CORMs have
been proposed as pharmaceutical agents by Motterlini, Mann,
and co-workers in 2002.28 Since then, the transition metal
carbonyls, in particular CORM-3 and CORM-2, have been
studied in detail.29 The biological and therapeutic activity of
these compounds have been largely assessed by in vitro, ex vivo,
and in vivo studies.30,31 Moreover, the water solubility and
stability in air of CORM-3 make it more suitable for
therapeutic use. Previous studies have indicated that CORM-
3 has therapeutic benefits in several animal models for a series
of diseases, including rheumatoid arthritis and myocardial
infarction.32,33 These studies also revealed an important clinical
feature of CORM-3; at therapeutic doses, no increase of
COHb (CO Hemoglobin) blood levels was detected. Starting
from these bases, other studies have been conducted in order
to explain the mechanism for the release of CO by
CORMs.34−38
In addition, there is a growing body of evidence indicating
the interaction of CORMs with distinct protein sub-
strates.39−41 In particular, Santos-Silva and co-workers
reported a rapid formation of stable adducts between the
His15 residue of lysozyme and the cis-Ru(CO)2 fragment of
CORM-3 as the result of the chloride ion, glycinate, and one
CO loss (Figure 2).35 Silvas et al. demonstrated, by
electrospray ionization-MS (ESI-MS) studies, that the Ru
carbonyl fragments of a [Ru(CO)3Cl2(1,3-thiazole)] species
bind to the His15 residue of lysozyme.42 The same reactivity
was also demonstrated for some Ru-based CORMs with azole
ligands.40 In both cases, data obtained by ESI-MS experiments
were confirmed by crystallographic studies. The collected
evidence revealed the tendency of Ru fragments to interact
with the Nε2 of His15 of lysozyme. Additional binding sites
have been reported to be close to Asp and Arg residues.40,42
The same reactivity was also reported for the Ru complex fac-
[Ru(CO)3(Cl2-N
1-thz)] and Aβ peptide 1−28. Valensin et al.
highlighted by 1D NMR the interaction of this complex with
the three His residues located in the N-terminal domain of Aβ
peptide.43
What makes the study of CORMs interaction with Aβ and
the investigation of CORM anti-aggregating properties even
more intriguing is the presence of a metal cation in their
structure. Indeed, since the discovery and application of the
most relevant platinum(II) complex, cis-[Pt(NH3)2Cl2], also
known as cisplatin,44,45 the development of metal complexes
addressed to different diseases including neurodegenerative
disorders, cancer, diabetes, inflammation, and cardiovascular
disease has significantly increased.46−48 From an AD
perspective, the interest in Aβ-targeted metal complexes as
anti-AD agents has increased over the past two decades.49−51
This is due to their appealing physiochemical properties and is
based on the finding that the amyloid plaques in AD patients
are enriched in transition-metal cations such as Cu, Fe, and
Zn.52−55 The finding that the dyshomeostasis of such metal
ions is correlated with AD56−58 led to the metal ion
hypothesis.59,60 Indeed, these cations possess a high binding
affinity for Aβ and their ability to mediate the aggregation
process in vitro has been assessed.57,61,62 Moreover, they are
also implicated in the production of ROS induced by Aβ.63,64
Many metal complexes have been used in AD as therapeutic,
diagnostic, and theranostic agents. The strategies adopted for
transition-metal complexes toward modulation of Aβ aggrega-
tion are different. Among them, the coordination, oxidation,
and hydrolysis of Aβ are the most common.65,66 The first metal
complexes with anti-aggregating properties were reported by
Barnham and co-workers in 2008.50 They demonstrated that
Pt2+-1, 10-phenantroline complexes interacted with the N-
terminal domain. The binding of Pt2+ to N-terminal histidine
residues was shown. This formation of the coordination adduct
was able to influence the behavior of the Aβ peptide. Brewer
and co-workers studied many complexes containing Pt2+ and
Ru2+ metal centers.67−69 Because of their attractive biological
features, ruthenium complexes are considered a valid
alternative to platinum-based ones.65 More recently, Messori
and co-workers presented a Ru2+ complex able to protect
cortical neurons against Aβ1−42 toxicity in an in vitro model.
49
However, it has been shown that most of these complexes
possess a higher affinity for fibrils than for oligomers. The fact
Figure 1. CORM structures. Chemical structures of two widely used
CORM molecules, CORM-2 and CORM-3.
Figure 2. CORM-3 protein interactions. Interactions of CORM-3 with lysozyme result in the loss of a chloride ion, glycinate, and one CO ligand,
leading to the rapid formation of stable adducts between the protein and the remaining Ru(CO)2.
35
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that Aβ oligomers are the most toxic species pushes research
toward the discovery of new complexes targeting these species.
Based on these premises and to the awareness that one of the
major strategies pursued for AD is focused on the stabilization
of the Aβ monomer in its native non-amyloidogenic
state,10,70,71 our aim was to explore the mechanism by which
CORMs 3 and 2 (Figure 1), or carbon monoxide, directly react
with Aβ1−42 and stabilize the peptide in its native form,
impeding the amyloidogenic conformational transition and
formation of toxic assemblies and fibrils. We have previously
reported that oxidized Aβ25−35 peptide is less prone to
aggregation.72 The aggregation pathway was previously
investigated by our group in an Aβ1−42 kinetic aggregation
study carried out using a multi-methodological approach.73
Therefore, the ability of CO-releasing molecules to directly
bind to Aβ1−42 and affect Aβ conformational transition and
aggregation has been investigated here by mass spectrometry
(MS), circular dichroism (CD) spectroscopy, and a thioflavin
T (ThT)-based fluorescence assay.
Each technique provides information on the interaction of
the Aβ amyloid peptide with metal complexes during the
different phases of its aggregation.72−76 Liquid chromato-
graph−MS (LC−MS) experiments provided evidence for the
formation of some stable noncovalent adducts between
CORMs and plasma proteins.38 ESI-MS is indeed one of the
most suitable techniques used to characterize complexes
formed by metal compounds and proteins,77 in particular
with the Aβ peptide.78−80 Consequently, the main question
that we address in this work is if CORMs can show other
functions in counteracting amyloid toxicity via a specific
reactivity with amyloid in addition to the reported beneficial
CO effects mediated by HO-1. Additionally, we investigated if
CO could react with Aβ1−42 in a similar fashion as oxygen.
2. RESULTS AND DISCUSSION
In order to study the CORMs/Aβ1−42 interaction, we carried
out a multi-methodological approach, which provides insights
into the stabilizing and anti-aggregating properties of amyloid
interacting molecules and allows elucidating their mechanism
of action. As Aβ toxicity is related to specific prefibrillary
species,81 it is important to follow the kinetics of the Aβ
assembly. Many compounds are characterized in terms of
interaction with fibrils but not with prefibrillary species.82
Therefore, this multi-methodological approach can give a more
comprehensive view of the CORMs/Aβ interaction. For
example, the anti-aggregating properties of myricetin were
shown by ThT-fluorescence assay, whereas its ability to
prevent structural changes in Aβ1−42 was confirmed by CD
studies.73,74 Moreover, MS techniques allowed monitoring the
modifications induced by myricetin on the monomer and the
first occurring Aβ1−42 self-assembly species.
75 In brief,
persistent level of monomers and the decreased formation of
ordered Aβ1−42 oligomeric aggregates in the presence of
myricetin were shown. In addition, these studies highlighted
the oxidation of the peptide at Met35 via formation of a
sulfoxide that is less prone to aggregation with a concomitant
loss of cytotoxicity and decrease in protein oxidation.75
Therefore, we applied a similar multi-methodological approach
and used myricetin as a reference inhibitor. The choice of
myricetin as the reference inhibitor is due to its proven anti-
aggregating properties. Moreover, its mechanism of action was
well characterized by different studies based on MS and our
multi-methodological approaches.72,73,75,76
2.1. Evaluation of Aβ1−42/CORM-3 Interaction by MS.
Evidence of CORMs protective effects against Aβ1−42 toxicity
in vitro and capacity to form stable adducts with histidine
residues of different proteins35 prompted us to investigate their
interaction with Aβ1−42 by MS analysis. Following the
experimental procedure previously reported by Bartolini et
al.,74 Aβ1−42 was incubated at 30 °C for 3 h in the absence and
in the presence of either CORM-2 or CORM-3 to achieve final
CORM/Aβ1−42 molar ratios (MRs) ranging from 0.1 to 10 to
gain insights into the reaction of CORMs with the His residues
of Aβ1−42.
In Figure 3a, the characteristic multicharged mass spectrum
of native Aβ1−42 is shown. The analysis of the ESI-MS spectra
exposed the generation of different charge states of the
monomer. The resulting signals were attributed to Aβ1−42
charge states ranging from 2 to 5 ions, the most intense being
[M + 4H]4+ at 1129.3 m/z, [M + 5H]5+ at 903.7 m/z, and [M
+ 6H]6+ at 753.3 m/z (Figure 3a). The deconvoluted MS
spectrum of Aβ1−42, not treated with CORMs (Figure 3b)
shows an intense signal at 4514 Da, which corresponds to the
molecular weight of the native form of the peptide. However,
when Aβ1−42 was incubated with CORM-3 at higher
concentration (CORM-3/Aβ1−42 = 10), new species at higher
molecular weights were detected (Figure 3c). The deconvo-
luted mass spectra revealed the addition of Ru(CO)2 to Aβ1−42.
In particular, a mass increment of 156 Da for the interaction of
Ru(CO)2 to each His residue was detectable, producing signals
at 4670, 4826, and 4982 Da, related to the addition of 1, 2, and
3 Ru(CO)2 moieties, respectively. These species derive from
the formation of stable adducts between Aβ1−42 and 1−3
Figure 3. Mass spectra of Aβ1−42/CORM assemblies. (Upper panel)
(a) Aβ1−42 multicharged mass spectrum and (b) Aβ1−42 deconvoluted
mass spectrum. (Lower panel) (c) Aβ1−42 deconvoluted mass
spectrum after its incubation with CORM-3 for 3 h at 30 °C
(molar ratio CORM-3/Aβ1−42 = 10).
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Ru(CO)2 groups from CORM-3 (molecular weight of 156
Da). As the primary sequence of Aβ1−42 contains three
histidine residues and CORMs are known to form stable
adducts with this amino acid,35 the Aβ1−42/CORMs reaction
may reasonably occur at this level (Figure 2). The extent of
Aβ1−42/CORMs adducts formation was found to be propor-
tional to CORM concentrations. Indeed, increased mono-, di-,
and tri-modified forms of the peptide (Figure 4b,c) were
detected at increasing CORM-2 and CORM-3 concentration.
Indeed, compared to CORM-3, the disappearance of the native
form of Aβ1−42 required a lower CORM-2 concentration (MR
= 5 instead of 10; Figure 4b,c). At low CORM molar ratio,
only the mono modified form of Aβ1−42 is evident, with the
native Aβ1−42 peptide concomitantly being transformed. By
increasing the CORM/Aβ1−42 molar ratio, peptide modifica-
tion was more pronounced, with the modification of the
monohistidine-modified form into bis- histidine- and tris-
histidine-modified Aβ1−42 adducts (Figure 4). In particular,
CORM-2 induced a complete disappearance of the native
Aβ1−42 form and the concomitant formation of Aβ1−42-
modified forms in which two or three histidine residues are
modified. This higher reactivity of CORM-2 can be explained
by the fact that two ruthenium moieties are present in the
CORM-2 structure, whereas CORM-3 bears only one.
2.2. Identification of Aβ1−42 Amino Acids Involved in
the Formation of Stable Adducts with CORM-3 and
CORM-2. A bottom-up approach was employed to assess the
Aβ1−42 amino acidic residues involved in the formation of
stable adducts with CORM-2 and 3. Aβ1−42 was incubated for
3 h at 30 °C in the absence and in the presence of CORMs at
final CORM/Aβ1−42 molar ratio of 5 or 10 before digestion
with trypsin. Peptides from the tryptic digestion of untreated
Aβ1−42 were all identified (Figure 1, Supporting Information).
Analysis of the tryptic digests, resulting from incubation with
CORMs, highlighted modification only at peptide 6−16,
independently from the type of CORM and molar ratio. In
particular, the mono-modified form of the peptide 6−16 (as di-
charged formm/z = 747.5) was detected after incubation
with CORM-3 at molar ratio equal to 5 (Figure 2, Supporting
Information). The identity of the adduct was confirmed by the
characteristic ruthenium isotope pattern, which perfectly
matched that previously reported by Hong and co-workers.83
MS/MS analysis of this peptide allowed final identification of
residue His6 as the amino acid residue involved in Ru(CO)2
binding (Figure 3 Supporting Information). This finding
confirms the tendency of ruthenium-containing molecules to
form adducts with His residues and to interact with binding
sites close to Asp and Arg residues as previously reported by
others.40,42,43 The identification of the second amino acid
residue involved in the formation of the di-adduct was not
possible because the di-modification of the peptide drastically
impacts the ionization efficiency and significantly reduces
signal intensity. The same phenomenon is also the cause of not
detecting the tri-modified peptide. However, as the mod-
ifications occur at 6−16 peptide containing three histidine
residues and according to the data reported in literature,43 it is
quite reasonable to assume that the second and the third
modification involve His 13 and 14.
2.3. Inhibition of Aβ1−42 Aggregation by CORM-3.
After assessing the capacity of CORMs to form stable adduct
with Aβ1−42, their anti-aggregation capacity was evaluated. We
have previously developed a reproducible Aβ1−42 aggregation
protocol, which allows the characterization of different
assembly species and a definition of their morphology,
molecular weight, and relative abundance.14 This information
is crucial to avoid confusing outcomes from both aggregation
studies and screening of inhibitors. Based on this multi-
methodological approach,73 the effects of CORM-3 on Aβ1−42
aggregation was monitored by different methodologies. ESI-
MS was applied for the quantification of monomers; CD
spectroscopy was used to obtain information on the secondary
structure,74,76 and a ThT fluorescence assay was applied to
assess fibrils formation.84 The use of different techniques
Figure 4. CORMs/Aβ1−42 adducts abundance as a function of
CORMs/Aβ1−42 molar ratio. The relative abundance of Aβ1−42 species
as a function of CORM-2 or CORM-3/Aβ1−42 molar ratio is reported
in panels a and b, respectively. Aβ1−42 (50 μM) and CORMs at
different concentrations (0−500 μM) were incubated at 30 °C for 3 h
and analyzed by ESI-MS. The Aβ1−42 species relative abundances were
derived from the deconvoluted ESI-MS spectrum.
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allows for a more comprehensive analysis of increasingly
complex interactions involved in prefibrillar species formation
during the aggregation process.85 Indeed, it was established
that Aβ toxicity is related to specific intermediates.81 In this
study, we employed the previously proposed multi-methodo-
logical approach to follow the Aβ1−42 aggregation process over
time in the presence and in the absence of CORM-3 at
different concentrations, using myricetin as the reference
inhibitor.
2.4. ESI-MS Analysis. ESI-MS has been previously used to
highlight the noncovalent interaction of myricetin and other
inhibitors with the native peptide.72,73,75,76 Using this
approach, it was possible to characterize the inhibitors,
determining their potency (IC50) and their capacity to
maintain the Aβ1−42 in its nonamyloidogenic, soluble
monomeric form. In the present study, our aim was to verify
whether Aβ1−42/CORMs interaction could favor the stabiliza-
tion of the nonamyloidogenic soluble form. Hence, an ESI-MS-
based approach was exploited for monitoring the decrease of
Aβ1−42 soluble monomers along with the mono-, di-, and tri-
Ru(CO)2-modified monomers formation. In detail, Aβ1−42 (50
μM) solution was incubated in the presence and in the absence
of 50 μM myricetin, 50 μM CORM-3, and 250 μM CORM-3.
At selected times, samples were analyzed by ESI-MS upon
addition of reserpine (30 μM) as an internal standard. In a
time course experiment, the aggregation was followed by
monitoring the ratio between the sum of all [M + 4H]4+
monomer species (native, mono, di-, and tri-Ru(CO)2-
modified) and the internal standard (IAβ1−42 monomers/IIs). The
charge state 4 was selected as it is endowed with the highest
intensity. As a result of the aggregation process, the signal of
the Aβ1−42 monomer progressively decreases until it almost
disappears in 48 h, when incubated alone (Ctrl sample, Figure
5). Conversely and in agreement with previous reports,75
myricetin was able to partially prevent monomer inclusion into
higher assemblies, slowing down the aggregation process.
Interestingly, CORM-3 was also able to interfere with amyloid
aggregation (Figure 5).
It is noteworthy that the inhibitory activity of CORM-3 is
higher at lower concentrations (1:1 molar ratio). This effect is
further elucidated in Figure 6, where the Aβ1−42 relative
abundance in the presence of CORM-3 at 5:1 and 1:1 ratio is
shown in the time course experiment. The Aβ1−42 in its native
form is not detectable after 24 h, when incubated in the
presence of CORM-3 at higher concentration. In contrast, at
1:1 molar ratio, CORM-3 seems to have an increased
stabilizing effect on the Aβ1−42 peptide in its soluble form, as
its signal is still detectable after 48 h. To make outcomes
trustable, considering the intrinsic variability of an aggregation
process, data were collected in duplicate from two independent
experiments carried out with different batches of the Aβ1−42
peptide. Future work could look to exploit this chemical insight
into biological settings to address the physiological relevance of
our observations. This could look to exploit human pluripotent
stem cells to maximize the translation aspects86 and additional
in vivo use of transgenic rodent models87 could look to provide
insight into CORMs effects on amyloidogenesis.
2.5. ThT Fluorescent Analysis. The selectivity of ThT
binding for β-sheet structures suggests that this assay can prove
the ability of compounds to interfere with fibril formation.84
Aβ1−42 (50 μM) samples were incubated at room temperature
with different amounts of CORM-3 to achieve final CORM-3/
Aβ1−42 MRs of 0.5, 1.0, and 5.0. After 48 h incubation, the
samples were diluted with glycine−NaOH buffer (50 mM, pH
8.5) containing ThT (1.5 μM). Fluorescence emission
intensity was monitored at 490 nm (λexc = 446 nm) for 300
s. Fluorescence intensities (IF) at 300 s were averaged after
subtracting the background fluorescence of 1.5 μM ThT
solution and of the tested compound. Inhibition of fibril
formation is expressed as the percent decrease of fluorescence
in comparison with the Aβ1−42 control sample. As shown in
Figure 7, CORM-3 at 25 μM strongly inhibited the formation
of Aβ1−42 fibrils to an extent similar to that by myricetin but at
Figure 5. Time-dependent inhibition of Aβ1−42 aggregation.
IAβ1−42 monomers/IIs values after 30 min, 24 and 48 h incubation.
Aβ1−42 was incubated in the absence (ctrl) and in the presence of
myricetin (50 μM), CORM-3 (50 μM), and CORM-3 (250 μM).
Figure 6. Time-dependent disappearance of Aβ1−42 monomer in the
presence of CORM-3. Relative abundance of native Aβ1−42 monomer
measured after incubation with CORM-3 at 50 and 250 μM is
reported ranging from 30 min to 48 h.
Figure 7. Inhibition of Aβ1−42 aggregation by ThT fluorescence assay.
Inhibition of fibrils formation obtained in the presence of myricetin
50 μM or CORM-3 at different concentrations is expressed as
percentage of fluorescence signal recorded in the presence and in the
absence of the inhibitor.
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a 2 times lower concentration. In agreement with the MS data
(Figure 5), the inhibitory effect was more pronounced at the
lowest CORM-3 concentration (lower IF values) at which the
extent of Aβ modification by CORM-3 is lower. This could be
explained considering that different degrees of modification
could lead to different effects on amyloid aggregation.
2.6. CD Analysis. Misfolding of Aβ1−42 is widely
recognized as the earliest step of amyloid aggregation. In
order to evaluate the inhibitory effect of CORM-3 on the
formation of amyloid aggregates, the change of the Aβ1−42
secondary structure was monitored over 50 h by CD
spectroscopy74 (Figures 8 and 9). The CD spectra of Aβ1−42
(Figure 8) show a clear transition from a prevalently unordered
conformation, characterized by two weak negative bands at
around 205 and 230 nm, to a β-strand structure, characterized
by a stronger negative band centered at 218 nm. Based on this
observation, the conformational change was monitored using
the difference between the CD signals at 205 nm (unordered)
and 218 nm (β-strand) as a function of time (Figure 9). Under
the used experimental conditions, the misfolding of Aβ1−42 is
complete in 48 h, with the mid-transition point occurring at
23.6 h.
CORM-3 strongly interferes with the Aβ1−42 folding process.
The CD spectra of the Aβ1−42/CORM-3 mixture at 1:1 molar
ratio (Figure 8b) show a perturbation of the electronic
properties of the peptide due to the formation of stable
adducts between CORM-3 and a single histidine residue of
Aβ1−42. The spectroscopic signature of β-strand structures,
however, was not observed throughout the considered time
frame, indicating that the conformational change was fully
inhibited (Figure 9). On the other hand, the formation of
double and triple Aβ1−42/CORM-3 adducts in the presence of
a 5:1 molar excess of CORM-3 (Figure 8c) induced a
conformational change of Aβ1−42 toward a β-strand-like
arrangement which, nevertheless, did not evolve into an
extensive amount of misfolded peptide (Figure 9). This
interpretation of CD data is supported by the relative
abundance of Aβ1−42/CORM-3 adducts at different times, as
shown by the ESI-MS analysis and by the ThT fluorescence
assay. Together, this suggests that the inhibition of amyloid
aggregation is highest when the interaction of CORM-3 with
Aβ1−42 involves a single histidine residue. The results obtained
via Aβ1−42 tryptic digestion confirmed the hypothesis that His6
is the first to be involved by CORM modification.
3. METHODS
3.1. Materials. 1,1,1,3,3,3-Hexafluoro-2-propanol, dimethyl
sulfoxide (DMSO), methanol, and acetonitrile (CH3CN)
(Chromasolv) were obtained from Sigma-Aldrich (Milan,
Italy). To prepare buffer solutions, potassium dihydrogen
phosphate, dipotassium hydrogen phosphate trihydrate,
glycine, sodium carbonate, sodium hydroxide, and sodium
chloride (Sigma-Aldrich, Milan, Italy) of analysis quality were
used. Human Aβ1−42 lyophilized powder was purchased from
Bachem (AG, Switzerland). Reserpine, myricetin (Myr),
CORM-3 and CORM-2, trypsin, and ThT were obtained
from Sigma-Aldrich (Milan, Italy). Purified water from Milli-
RX system (Millipore, Milford, MA) was used to prepare
buffers and standard solutions. Nitrocellulose (0.22 μm) and
nylon (0.20 μm) membrane filters (Millipore, Carrigtwohill,
Ireland B.V.) were employed to filter buffers and solutions.
CORM-3 and CORM-2 stock solutions were obtained by
dissolving the compounds in water or DMSO, respectively, in
order to get the 100mM starting concentration. Myricetin was
solubilized in DMSO at a stock concentration of 1 mg/mL. All
compounds were from Sigma-Aldrich (Milan, Italy).
3.2. Aβ1−42 Preparation. Following the previously
published procedure,73,74 1 mg of Aβ1−42 lyophilized powder
was pretreated overnight with 1400 μL of HFIP, portioned,
and stored at −20 °C after solvent evaporation.
3.3. Characterization of Aβ1−42-CORMs Adducts. An
Aβ1−42 aliquot (corresponding to 0.0368 μmol) was solubilized
in 69.5 μL of a freshly prepared mixture consisting of CH3CN/
300 μM Na2CO3/250 mM NaOH (48.3/48.3/3.4, v/v/v) to
obtain a 500 μM stock solution. CORM-2 100 mM stock
Figure 8. CD spectra of Aβ1−42 samples at different times after sample preparation. (a) Aβ1−42 in the absence of CORM-3. (b) Aβ1−42 in the
presence of CORM-3 at 1:1 molar ratio. (c) Aβ1−42 in the presence of excess CORM-3 at 5:1 molar ratio.
Figure 9. Kinetics of Aβ1−42 misfolding as monitored by CD
spectroscopy. Samples: Aβ1−42 in the absence of CORM-3 (circles,
solid line); Aβ1−42 in the presence of CORM-3 at 1:1 molar ratio
(squares, dashed line). Aβ1−42 in the presence of excess CORM-3 at
5:1 molar ratio (diamonds, dotted line).
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solution was prepared in DMSO, whereas the CORM-3 100
mM stock solution was prepared in water. Stock solutions of
the CORMs were kept at −20 °C before use.
To study the formation of stable adducts between Aβ1−42
and CORM molecules, 3 μL of the Aβ1−42 stock solution was
diluted with 27 μL of 10 mM phosphate buffer pH 7.7
containing 11 mM NaCl, in the absence and in the presence of
CORM-2 or CORM-3 at 5.50, 13.7, 27.5, 55.0, 110, 275, and
550 μM concentrations to achieve final CORM/Aβ1−42 MR
equal to 0.0, 0.1, 0.25, 0.5, 1.0, 2.0, 5.0, and 10, respectively.
Samples were incubated at 30 °C for 3 h and finally diluted 1:1
with water before the LC−MS analysis. Experiments were
performed in duplicate.
3.4. Inhibition Studies. 3.4.1. MS-Based Assay. Aβ1−42
stock solution was diluted 1:10 with 10 mM phosphate buffer
pH 7.7 containing NaCl 11 mM, in the absence and in the
presence of CORM-3 at 55.0 and 275 μM concentrations (to
achieve the final CORM-3/Aβ1−42 MR equals to 0.0, 1.0, and
5.0, respectively) and in the presence of 55.5 μM Myr (final
Myr/Aβ1−42 MR 1: 1). Samples were incubated at room
temperature (RT) and, at selected times, 10 μL were diluted
1:1 with reserpine solution (30 μM in water/MeOH, 50/50, v/
v) employed as the internal standard. The analysis was
performed by the LC−MS analysis as reported in Section 2.5.
Two independent experiments, each performed in duplicate,
were carried out using two different batches of Aβ1−42.
3.4.2. ThT-Based Fluorometric Assay. Aβ1−42 stock solution
was diluted 1:10 with 10 mM phosphate buffer pH 7.7
containing 11 mM NaCl, in the absence or presence of
CORM-3 at 27.5, 55.0, and 275 μM concentration to achieve
the final CORM-3/Aβ1−42 MR equal to 0.0, 0.5, 1.0, and 5.0,
respectively. Samples were incubated at RT for 48 h and finally
diluted with the glycine−NaOH buffer (50 mM, pH 8.5)
containing ThT (1.5 μM) to achieve the final volume of 2.0
mL. Fluorescence emission was monitored by a Jasco FP-6200
spectrofluorometer (Jasco, Tokyo, Japan) using a 3 mL quartz
cell. For each sample, the fluorescence emission signal was
monitored at 490 nm (λex = 446 nm) with excitation and
emission slits of 2 nm bandwidth. A time scan was performed,
and the fluorescence intensity values at the plateau (300 s)
were averaged after subtracting the background fluorescence
from 1.5 μM ThT.
3.4.3. LC−MS Analysis. LC−MS analyses were performed
by an Agilent 1200 Series (Walbronn, Germany) coupled with
an ESI-Q-ToF mass spectrometer equipped with a Z-spray ion
source (Micromass, Manchester, UK). Flow injection analyses
were performed by employing water/acetonitrile/FA (70/30/
0.1; v/v/v) as the mobile phase at the flow rate of 0.1 mL/min.
The injection volume was 5 μL. The capillary voltage was set at
3000 V, the cone voltage was 40 V, the capillary temperature
was 100 °C, while the desolvation temperature was 300 °C.
Mass spectra were recorded in total ion current (TIC), within
1000 and 2000 m/z, in positive polarity. The Aβ1−42 baseline-
subtracted spectrum (m/z 1100−1700) was deconvoluted
onto a true mass scale using the maximum entropy
(MaxEnt1)-based software supplied with MassLynx software.
The output parameters were mass range: 4100−5200 Da and
resolution: 2 Da/channel. The uniform Gaussian model was
used, with 0.63 Da width at half height. The Aβ1−42 (alone or
forming a complex with CORMs) relative abundance was
calculated by dividing the corresponding form intensity by the
sum of all forms intensities and multiplying them by 100. Data
were analyzed by Excel.
3.4.4. LC-ESI-MS/MS Analysis. A 3 μL aliquot of Aβ1−42
stock solution (500 μM) was diluted ten folds with 10 mM
phosphate buffer pH 7.7 containing 11 mM NaCl, in the
absence and in the presence of CORM-2 or CORM-3 to
achieve final CORM/Aβ1−42 MR equal to 5.0 and 10. Samples
were incubated for 3 h at 30 °C, then 1 μL of trypsin (1 μg/
μL; Sigma T1426) was added and samples were incubated
overnight at 37 °C to allow peptide digestion. Aβ1−42 tryptic
digest (10 μL), corresponding to 485 pmol, was analyzed by
using an Agilent 1100 Series system (Walbronn, Germany).
Analyses were performed on a C18 column (Aeris peptide XB-
C18; 150 × 2.1 mm; 3.5 μm; Phenomenex). Mobile phases A
[water/acetonitrile/FA (99/1/0.1, v/v/v)] and B [water/
acetonitrile/FA (1/99/0.1, v/v/v)] were used to develop a
gradient. The solvent gradient was set as follows: A−B from
(98:8, v/v) to (40:60, v/v) in 20 min; (40:60, v/v) for 2 min.
The column was equilibrated with the mobile phase
composition of the starting conditions for 10 min before the
next injection. MS analysis was performed on the Q-ToF
Micro hybrid analyzer (Micromass, Manchester, UK) with a Z-
spray ion source. The ESI-Q-ToF source temperature was set
at 100 °C, the capillary voltage at 3.0 kV, and the cone voltage
at 35 V. Peptide ions within a m/z 400−1700 survey scan mass
range were analyzed for subsequent fragmentation. 2+, 3+, and
4+ charged ions exceeding a threshold abundance (TIC value:
10 counts/s) were selected for MS/MS analyses. From a single
survey scan, 4 ions were selected for subsequent fragmentation.
Scan returns to mass survey mode when the ion intensity falls
below 5 counts/s or after 8 s. Scan time was 1 s for the parent
ion and 1 s for the MS/MS ions. The collision energy was
selected using charge state recognition.
3.4.5. CD Analysis. CD measurements were carried out at
25 °C in the 260−200 nm spectral range on a Jasco (Tokyo,
Japan) J-810 spectropolarimeter equipped with a PTC-423S
Peltier-type temperature control system, using QS quartz cells
(Hellma Italia, Milan, Italy) with a 0.1 cm path length, a 2 nm
spectral bandwidth, a 0.5 nm data interval, a 20 nm min−1
scanning speed, and a 2 s data integration time. Aβ1−42 samples
(50 μM, 200 μL final volume), either in the absence or in the
presence of CORM-3 at both 1 and 5 MR, were prepared as
previously described. The CD spectra of all samples were
measured at different times after preparation (up to 52 h) to
follow the time evolution of the secondary structure of Aβ1−42
and evaluate the effect of CORM-3 on the misfolding process.
Baseline correction was performed by subtracting the spectral
contribution of phosphate buffer (8.7 mM) containing NaCl
(10 mM), Na2CO3 (14.5 mM), NaOH (0.85 mM), and
acetonitrile (8.2%, v/v); CORM-3 was not included in the
blank solution, as it shows no CD signal in the spectral range
considered in the analysis. Solvent-corrected CD spectra were
then converted to molar units per residue (Δεres, M−1 cm−1)
and plotted using the Bezier smoothing algorithm provided by
the Gnuplot software (version 5.2.2, http://gnuplot.
sourceforge.net). The conformational change of Aβ1−42 was
monitored by plotting the difference between the unsmoothed
CD signals at 205 and 218 nm (Δεres,205 − Δεres,218) as a
function of time.
4. CONCLUSIONS
The applied multi-methodological approach provides a de-
tailed analysis of the in vitro Aβ1−42 kinetics by detailing the
formation of diverse assembly species. Combination of ThT
assay, ESI-MS analysis, and CD studies grant reliable
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information on the overall fibrilization process as well as the
identification of aggregation inhibitors and the nature of this
inhibition (CD or ESI-MS).
Specifically, the ESI-MS data demonstrated that CORM-3
and CORM-2 directly interact with Aβ1−42, producing stable
soluble adducts. This likely occurs through histidine
modification via the addition of the Ru(CO)2 moiety. Indeed,
the results obtained by the tryptic digestion experiment
confirmed the hypothesis that His6 is the first His residue to
be involved in Aβ modification by studied CORMs.
By varying the molar ratio, incubation time and type of
CORM, the extent of Aβ1−42 modification changed. CORM-2,
possessing two Ru atoms per molecule, was effective in
modifying Aβ1−42 at a lower molar ratio than CORM-3. The
higher reactivity highlighted for CORM-2 is certainly due to
the different stoichiometry of the beta amyloid: metal reaction.
For CORM-2, this rate is twice that for CORM-3. Moreover,
Kumar and co-workers reported a much higher binding affinity
of the binuclear complex, [(bpy)2Ru
2+ (dpp)Pt2+Cl2]
2+ instead
of the mononuclear [(dpp)Pt2+Cl2] toward Aβ.
51 The results
revealed the mono histidine-modified Aβ1−42 to be more
soluble and less prone to aggregate than the double- or triple-
modified Aβ1−42, implying that the higher stabilizing effect is
reached at lower Aβ1−42/CORM-3 molar ratio. CD studies
highlighted that, in the mono-modified form, the β-strand
conformational change is fully inhibited. On the other hand,
the formation of double and triple Aβ1−42/CORM-3 adducts in
the presence of a 1:5 molar excess of CORM-3 induces a
conformational change of Aβ1−42 toward a β-strand-like
arrangement which, nevertheless, does not evolve into an
extensive misfolding of the peptide. This interpretation of CD
data is supported by the relative abundance of Aβ1−42/CORM-
3 adducts at different times, as observed by ESI-MS analysis,
and by a ThT fluorescence assay, suggesting that the inhibition
of amyloid aggregation is the highest when the interaction of
CORM-3 with Aβ1−42 involves a single histidine residue.
Therefore, a novel mechanism of action of the CORMs was
determined with reference to their capacity to create some
stable adducts with Aβ1−42 amino acidic chain.
CORM-3 emerged as a promising inhibitory agent toward
Aβ1−42 aggregation. MS and ThT studies also supported the
identification of the optimal CORM-3/Aβ1−42 ratio for the best
inhibitory effect.
This study contributes to the evaluation of the spectrum of
activities exerted by CORM-3. In terms of therapeutic
potential, the highlighted antiaggregating properties nicely
complement the already known neuroprotective and anti-
inflammatory properties of CORM-3.25,26,88,89 Therefore, we
can use these findings as a further potential mechanism
explaining the CORMs-mediated reduction of Aβ toxicity
previously reported in vitro and additionally in vivo.
Furthermore, the fact that CORM-3 does not increase CO
levels in vivo90 and that the CO trapped by hemoglobin in
therapeutic conditions is below the toxicity threshold (in
humans, this threshold is close to 10% COHb)91 make these
molecules appealing for further developments.
Taken together, the outcomes of this study open up new
avenues to explore the potential of CORMs to inhibit
aggregation of other disease-related peptides, such as alpha
synuclein.92
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(12) Doens, D.; Fernańdez, P. L. Microglia receptors and their
implications in the response to amyloid β for Alzheimer’s disease
pathogenesis. J. Neuroinflammation 2014, 11, 48.
(13) Garwood, C. J.; Pooler, A. M.; Atherton, J.; Hanger, D. P.;
Noble, W. Astrocytes are important mediators of Aβ-induced
neurotoxicity and tau phosphorylation in primary culture. Cell
Death Dis. 2011, 2, e167.
(14) Verkhratsky, A.; Rodríguez-Arellano, J. J.; Parpura, V.; Zorec, R.
Astroglial calcium signalling in Alzheimer’s disease. Biochem. Biophys.
Res. Commun. 2017, 483, 1005−1012.
(15) Rodríguez-Arellano, J. J.; Parpura, V.; Zorec, R.; Verkhratsky, A.
Astrocytes in physiological aging and Alzheimer’s disease. Neuroscience
2016, 323, 170−182.
(16) Yeh, C.-Y.; Vadhwana, B.; Verkhratsky, A.; Rodríguez, J. J. Early
astrocytic atrophy in the entorhinal cortex of a triple transgenic animal
model of Alzheimer’s disease. ASN Neuro 2011, 3, AN20110025.
(17) Weaver, L. K. Clinical practice. Carbon monoxide poisoning. N.
Engl. J. Med. 2009, 360, 1217−1225.
(18) Chang, K.-H.; Chang, M.-Y.; Muo, C.-H.; Wu, T.-N.; Chen, C.-
Y.; Kao, C.-H. Increased risk of dementia in patients exposed to
nitrogen dioxide and carbon monoxide: a population-based
retrospective cohort study. PLoS One 2014, 9, e103078.
(19) Brouard, S.; Otterbein, L. E.; Anrather, J.; Tobiasch, E.; Bach,
F. H.; Choi, A. M. K.; Soares, M. P. Carbon monoxide generated by
heme oxygenase 1 suppresses endothelial cell apoptosis. J. Exp. Med.
2000, 192, 1015−1026.
(20) Otterbein, L. E.; Bach, F. H.; Alam, J.; Soares, M.; Tao Lu, H.;
Wysk, M.; Davis, R. J.; Flavell, R. A.; Choi, A. M. K. Carbon
monoxide has anti-inflammatory effects involving the mitogen-
activated protein kinase pathway. Nat. Med. 2000, 6, 422−428.
(21) Otterbein, L. E.; Zuckerbraun, B. S.; Haga, M.; Liu, F.; Song,
R.; Usheva, A.; Stachulak, C.; Bodyak, N.; Smith, R. N.; Csizmadia, E.;
Tyagi, S.; Akamatsu, Y.; Flavell, R. J.; Billiar, T. R.; Tzeng, E.; Bach, F.
H.; Choi, A. M. K.; Soares, M. P. Carbon monoxide suppresses
arteriosclerotic lesions associated with chronic graft rejection and with
balloon injury. Nat. Med. 2003, 9, 183−190.
(22) Hettiarachchi, N.; Dallas, M.; Al-Owais, M.; Griffiths, H.;
Hooper, N.; Scragg, J.; Boyle, J.; Peers, C. Heme oxygenase-1 protects
against Alzheimer’s amyloid-β(1-42)-induced toxicity via carbon
monoxide production’. Cell Death Dis. 2014, 5, e1569.
(23) Hettiarachchi, N. T.; Boyle, J. P.; Dallas, M. L.; Al-Owais, M.
M.; Scragg, J. L.; Peers, C. Heme oxygenase-1 derived carbon
monoxide suppresses Aβ. Cell Death Dis. 2017, 8, e2884.
(24) Ma, T.; Chen, Y.; Vingtdeux, V.; Zhao, H.; Viollet, B.;
Marambaud, P.; Klann, E. Inhibition of AMP-activated protein kinase
signaling alleviates impairments in hippocampal synaptic plasticity
induced by amyloid β. J. Neurosci. 2014, 34, 12230−12238.
(25) Vieira, H. L. A.; Queiroga, C. S. F.; Alves, P. M. Pre-
conditioning induced by carbon monoxide provides neuronal
protection against apoptosis. J. Neurochem. 2008, 107, 375−384.
(26) Kim, H. J.; Joe, Y.; Chen, Y.; Park, G. H.; Kim, U.-H.; Chung,
H. T. Carbon monoxide attenuates amyloidogenesis via down-
regulation of NF-κB-mediated BACE1 gene expression. Aging Cell
2019, 18, e12864.
(27) Chen, J. Heme oxygenase in neuroprotection: from
mechanisms to therapeutic implications. Rev. Neurosci. 2014, 25,
269−280.
(28) Motterlini, R.; Mann, B. E. P. A. Therapeutic delivery of carbon
monoxide. EP2135605A2, 2002.
(29) Motterlini, R.; Clark, J. E.; Foresti, R.; Sarathchandra, P.; Mann,
B. E.; Green, C. J. Carbon monoxide-releasing molecules: character-
ization of biochemical and vascular activities. Circ. Res. 2002, 90,
E17−E24.
(30) Nobre, L. S.; Seixas, J. D.; Romao, C. C.; Saraiva, L. M.
Antimicrobial action of carbon monoxide-releasing compounds.
Antimicrob. Agents Chemother. 2007, 51, 4303−4307.
(31) Desmard, M.; Davidge, K. S.; Bouvet, O.; Morin, D.; Roux, D.;
Foresti, R.; Ricard, J. D.; Denamur, E.; Poole, R. K.; Montravers, P.;
Motterlini, R.; Boczkowski, J. A carbon monoxide-releasing molecule
(CORM-3) exerts bactericidal activity against Pseudomonas aerugi-
nosa and improves survival in an animal model of bacteraemia. FASEB
J. 2009, 23, 1023−1031.
(32) Vadori, M.; Seveso, M.; Besenzon, F.; Bosio, E.; Tognato, E.;
Fante, F.; Boldrin, M.; Gavasso, S.; Ravarotto, L.; Mann, B. E.;
Simioni, P.; Ancona, E.; Motterlini, R.; Cozzi, E. In vitro and in vivo
effects of the carbon monoxide-releasing molecule, CORM-3, in the
xenogeneic pig-to-primate context. Xenotransplantation 2009, 16, 99−
114.
(33) Wang, G.; Hamid, T.; Keith, R. J.; Zhou, G.; Partridge, C. R.;
Xiang, X.; Kingery, J. R.; Lewis, R. K.; Li, Q.; Rokosh, D. G.; Ford, R.;
Spinale, F. G.; Riggs, D. W.; Srivastava, S.; Bhatnagar, A.; Bolli, R.;
Prabhu, S. D. Cardioprotective and antiapoptotic effects of heme
oxygenase-1 in the failing heart. Circulation 2010, 121, 1912−1925.
(34) Johnson, T. R.; Mann, B. E.; Teasdale, I. P.; Adams, H.; Foresti,
R.; Green, C. J.; Motterlini, R. Metal carbonyls as pharmaceuticals?
[Ru(CO)3Cl(glycinate)], a CO-releasing molecule with an extensive
aqueous solution chemistry. Dalton Trans. 2007, 15, 1500−1508.
(35) Santos-Silva, T.; Mukhopadhyay, A.; Seixas, J. D.; Bernardes, G.
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